BIA
ALLO icon

Bell Investment Advisors’s Allogene Therapeutics ALLO Stock Holding History

Bell Investment Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01K Hold
486
– – ﹤0.01% 1528
2026
Q1 		$1.19K Hold
486
– – ﹤0.01% 1505
2025
Q4 		$666 Hold
486
– – ﹤0.01% 1648
2025
Q3 		$603 Buy
+486
New +$579 ﹤0.01% 1703
2024
Q3 		– Sell
-161
Closed -$376 – 1883
2024
Q2 		$376 Hold
161
– – ﹤0.01% 1883
2024
Q1 		$720 Hold
161
– – ﹤0.01% 1692
2023
Q4 		$517 Buy
+161
New +$457 ﹤0.01% 1823
2021
Q4 		– Sell
-88
Closed -$2K – 1755
2021
Q3 		$2K Buy
+88
New +$2.09K ﹤0.01% 1014

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Bell Investment Advisors's ALLO Position: Q2 2026 in Review

Bell Investment Advisors held its Allogene Therapeutics (ALLO) position steady in Q2 2026 at 486 shares worth $1.01K. The position accounts for ﹤0.01% of the portfolio, ranked #1528.

Bell Investment Advisors first reported a position in ALLO in Q3 2021 and has held it in 8 quarters since. The position peaked at $2K in Q3 2021. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Bell Investment Advisors held 486 shares of Allogene Therapeutics worth $1.01K as of Q2 2026.
  • Bell Investment Advisors left its Allogene Therapeutics share count unchanged in Q2 2026.
  • Allogene Therapeutics made up ﹤0.01% of Bell Investment Advisors's portfolio in Q2 2026, its #1528 holding.
  • Bell Investment Advisors first reported a position in Allogene Therapeutics in Q3 2021 and has held it in 8 quarters since.
  • Bell Investment Advisors's Allogene Therapeutics position peaked at $2K in Q3 2021.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.